In vivo and in vitro characterization of ethyl methanesulfonate pharmacokinetics in animals and in human

Toxicology Letters

Volumn 190, Issue 3, 2009, Pages 303-309

  Lavé, Thierry ^a   Birnböck, Herbert ^a   Götschi, Andreas ^a   Ramp, Thomas ^a   Pähler, Axel ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Animals; Covalent binding; Ethyl methanesulfonate; Haemoglobin ethyl valine adduct; Pharmacokinetics; Viracept

Indexed keywords

HEMOGLOBIN; MESYLIC ACID ETHYL ESTER; NELFINAVIR;

ABSORPTION; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BIOAVAILABILITY; CHEMICAL ANALYSIS; CLEARANCE; CONTROLLED STUDY; DRUG CONTAMINATION; HALF LIFE TIME; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; RAT; SPECIES DIFFERENCE; TOXICOKINETICS;

ALKYLATING AGENTS; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG CONTAMINATION; ETHYL METHANESULFONATE; HALF-LIFE; HEMOGLOBINS; HIV PROTEASE INHIBITORS; HUMANS; MACACA FASCICULARIS; MALE; MICE; MICROSOMES, LIVER; MUTAGENS; NELFINAVIR; RATS; RISK ASSESSMENT; SPECIES SPECIFICITY; TABLETS; VALINE;

ANIMALIA; MACACA FASCICULARIS; MUS; RATTUS;

EID: 69549094349     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.toxlet.2009.07.030     Document Type: Article

References (20)

1. Beutler E., and Waalen J. The definition of anemia: what is the lower limit of normal of the blood haemoglobin concentration?. Blood 107 (2006) 1747-1750
2. Carmella S.G., Chen M., Villalta P.W., Gurney J.G., Hatsukami D.K., and Hecht S.S. Ethylation and methylation of haemoglobin in smokers and non-smokers. Carcinogenesis 23 (2002) 1903-1910
3. Cumming R.B., and Walton M.F. Fate and metabolism of some mutagenic alkylating agents in the mouse. I. Ethyl methanesulfonate and methyl methanesulfonate at sublethal dose in hybrid males. Mutat. Res. 10 (1970) 365-377
4. Delp M.D., Evans M.V., and Duan C. Effects of aging on cardiac output, regional blood flow, and body composition in Fischer-344 rats. J. Appl. Physiol. 85 (1998) 1813-1822
5. Dressman J.B., Vertzoni M., Goumas K., Reppas C., et al. Estimating drug solubility in the gastrointestinal tract. Adv. Drug Deliv. Rev. 59 7 (2007) 591-602
6. Froese-Gertsen E.E., Konzak C.F., Foster R., and Nilan A.R. Correlations between some chemical and biological reactions of ethyl methanesulfonate. Nature 198 (1963) 447-448
7. Gocke, E., Müller, L., Pfister, T., Buergin, this issue-a. Literature review on the genotoxicity, reproductive toxicity, and carcinogenicity of ethyl methanesulfonate. Toxicol. Lett.
8. Gocke, E., Müller, L., Ballantyne, M., Whitwell, J., this issue-b. Genotoxicity studies with ethyl methanesulfonate for micronuclei and lacZ gene mutation in mice. Toxicol. Lett.
9. Janssen B., Debets J., Leenders P., and Smits J. Chronic measurement of cardiac output in conscious mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. 282 (2002) R928-R935
10. Kreiss M.C., Wu H.M., et al. Noninvasive measurement of cardiovascular function in mice with high-temporal-resolution small-animal PET. J. Nucl. Med. 47 (2006) 974-980
11. Lavé, T., Paehler, A., Grimm, H.P., Gocke, E., and Müller, L., this issue. Modelling of patient EMS exposure: translating pharmacokinetics of EMS in vitro and in animals into patients. Toxicol. Lett.
12. Müller, L., Singer, T., this issue. EMS in Viracept-a compilation of events in 2007 and 2008 from the non-clinical point of view. Toxicol. Lett.
13. Müller, L., Gocke, E., Lavé, T., Pfister T., this issue. Ethyl methanesulfonate toxicity in Viracept-a comprehensive human risk assessment based on threshold data for genotoxicity. Toxicol. Lett.
14. Murthy M.S.S., Calleman C.J., Osterman-Golkar S., Segerbäck D., and Svensson K. Relationships between ethylation of haemoglobin, ethylation of DNA and administered amount of ethyl methanesulfonate in the mouse. Mutat. Res. 127 (1984) 1-8
15. Neumann H.G. Analysis of haemoglobin as a dose monitor for alkylating and arylating agents. Arch. Toxicol. 56 (1984) 1-6
16. Osterman-Golkar S., Ehrenberg L., Segerbäck D., and Hällström I. Evaluation of genetic risks of alkylating agents. II. Haemoglobin as a dose monitor. Mutat. Res. 34 (1976) 1-10
17. O'Flaherty E.J., Inskip M.J., Franklin P., Durbin P.W., Manton W.I., and Baccanale C.L. Evaluation and modification of a physiologically based model of lead kinetics using data from a sequential isotope study in cynomolgus monkeys. Toxicol. Appl. Pharmacol. 149 (1998) 1-16
18. Pfister, T., Eichinger-Chapelon, A., this issue. General toxicity studies with ethyl methanesulfonate. Toxicol. Lett.
19. Poirier V., and Calleman C.J. The nucleophilic reactivity of valine methylamide: a model of the N-terminal valine residues of hemoglobin. Acta Chem. Scand. B37 (1983) 817-822
20. Törnqvist M., Fred C., Haglund J., Helleberg H., Paulsson B., and Rydberg P. Protein adducts: quantitative and qualitative aspects of their formation, analysis and applications. J. Chromatogr. B 778 (2002) 279-308